Last reviewed · How we verify
Infanrix Hib™
Infanrix Hib is a combination vaccine that stimulates the immune system to produce antibodies against diphtheria, tetanus, pertussis, and Haemophilus influenzae type b (Hib) bacteria.
Infanrix Hib is a combination vaccine that stimulates the immune system to produce antibodies against diphtheria, tetanus, pertussis, and Haemophilus influenzae type b (Hib) bacteria. Used for Primary immunization against diphtheria, tetanus, pertussis, and Haemophilus influenzae type b in infants and children.
At a glance
| Generic name | Infanrix Hib™ |
|---|---|
| Sponsor | GlaxoSmithKline |
| Drug class | Combination vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
The vaccine contains inactivated toxoids of diphtheria and tetanus, acellular pertussis antigens, and conjugated Hib polysaccharide antigen. These components trigger adaptive immune responses, generating protective antibodies and cellular immunity against these four pathogens. This prevents infection by these bacteria in vaccinated individuals.
Approved indications
- Primary immunization against diphtheria, tetanus, pertussis, and Haemophilus influenzae type b in infants and children
Common side effects
- Injection site pain, redness, or swelling
- Fever
- Irritability or fussiness
- Drowsiness
- Loss of appetite
Key clinical trials
- Study to Evaluate Antibody Persistence in Children Previously Vaccinated With Infanrix Hexa™ or Infanrix-IPV/Hib™ (PHASE4)
- Immunogenicity and Safety of Meningococcal Vaccine GSK 134612 Co-administered With Pneumococcal and DTPa-HBV-IPV/Hib Vaccines (PHASE3)
- Study of Long-term Antibody Persistence After a Booster Dose of Menitorix Vaccine (PHASE4)
- Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine Administered as a Booster Dose (PHASE2)
- Safety of GSK Biologicals' Infanrix-IPV+HibTM Vaccine in Healthy Vietnamese Toddlers (PHASE3)
- Immunogenicity & Safety Study of Combined/Separate Vaccine(s) Against Common Diseases in Infants (2,4,6 Months of Age). (PHASE3)
- Evaluate Safety and Immunogenicity of a Booster Dose of Pneumococcal Conjugate Vaccine in Preterm Born Infants. (PHASE3)
- Pneumococcal Vaccine Booster Study in Healthy Children 11-18 Months Old Previously Primed With the Same Vaccines (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |